Gordon Dougan

CEO International Cruise Summit • Cruises News Media Group

Professor Cambridge University Institute of Immunology & Infectious Disease
Professor Gordon Dougan is a world authority on vaccines, genomics and the epidemiology of infectious diseases including antibiotic resistance. He has contributed to the development of several vaccines (e.g. whooping cough, cholera, typhoid) and was previously voted in the top ten most influential people in the vaccine world. He has served on numerous international bodies and organisations including, the World Health Organization, the GSK Institute for Global Health, the International Vaccine Institute (Korea) and Wellcome. He is currently a Professor in the Department of Medicine, University of Cambridge and was formerly Head of Pathogen Research at the Wellcome Sanger Institute.He has worked in the Pharmaceutical industry developing vaccine for over a decade.
Gordon was educated in his home town of Scunthorpe in England and received his BSc and PhD from the University of Sussex, where he studied antibiotic resistance. He completed his postdoctoral research at the University of Washington (Seattle) in the laboratory of Professor Stanley Falkow. He holds Masters Degrees from Trinity College Dublin and Wolfson College, University of Cambridge. He is a visiting professor at the London School for Hygiene and Tropical Medicine and an adjunct professor at Monash and Melbourne universities in Australia.
Gordon has worked extensively with WHO. He chaired the Novartis Vaccine SAB for many years. He served on the Board of Directors of the Hilleman Laboratories where he helped bring in the stabilised oral cholera (Hikojima/Hillcol) vaccine now being developed in India. Gordon has founded companies including Microbiotica working on novel approaches to tackling infections via bacteriotherapies. Gordon is currently a Professor in the Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge and an advisor to Wellcome.